Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Disclosure
Biotech
Aptinyx pauses phase 2 trial of higher dose PTSD med
Trouble continues for Aptinyx after it suddenly paused initiation of the higher dose arm of a phase 2b trial for a PTSD med.
Max Bayer
Apr 20, 2022 1:08pm
José Baselga resigns from MSK over disclosure controversy
Sep 14, 2018 9:00am
Reuters: Fortress’ in-house broker raised $240M for its biotechs
Aug 2, 2018 3:23pm
Icon launches new electronic financial disclosure form software
May 22, 2018 8:48am
